These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38053391)

  • 1. The Incidence of Torsades de Pointes With Perioperative Triple Antiemetic Administration.
    Nuttall GA; Reed AM; Pham Louis KD; Oyen LJ; Marsland SP; Ackerman MJ
    Ann Pharmacother; 2023 Dec; ():10600280231215786. PubMed ID: 38053391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The incidence of torsades de pointes with peri-operative low-dose ondansetron administration.
    Nuttall GA; Voogd SC; Danke H; Warner PA; Oyen LJ; Marienau MS; Ackerman MJ
    Pharmacotherapy; 2022 Apr; 42(4):292-297. PubMed ID: 35124842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does low-dose droperidol increase the risk of polymorphic ventricular tachycardia or death in the surgical patient?
    Nuttall GA; Malone AM; Michels CA; Trudell LC; Renk TD; Marienau ME; Oliver WC; Ackerman MJ
    Anesthesiology; 2013 Feb; 118(2):382-6. PubMed ID: 23291623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QT prolongation, torsades des pointes, and cardiac arrest after 4 mg of IV ondansetron.
    Orozco BS; Lee SC; Fuchs RT; Fushianes GD; Cole JB
    Am J Emerg Med; 2023 Jun; 68():214.e3-214.e6. PubMed ID: 37085406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic ventricular tachycardia, ischaemic ventricular fibrillation, and torsade de pointes: importance of the QT and the coupling interval in the differential diagnosis.
    Rosso R; Hochstadt A; Viskin D; Chorin E; Schwartz AL; Tovia-Brodie O; Laish-Farkash A; Havakuk O; Gepstein L; Banai S; Viskin S
    Eur Heart J; 2021 Oct; 42(38):3965-3975. PubMed ID: 33693589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
    Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased ventricular ectopy precedes Torsades de Pointes in patients with prolonged QT.
    Marill KA; Lopez S; Hark D; Spahr J; Kapadia N; Liu SW
    J Electrocardiol; 2023; 80():17-23. PubMed ID: 37105125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, therapeutic response, and outcome of ventricular tachycardia in the out-of-hospital setting: a comparison of monomorphic ventricular tachycardia, polymorphic ventricular tachycardia, and torsades de pointes.
    Brady WJ; DeBehnke DJ; Laundrie D
    Acad Emerg Med; 1999 Jun; 6(6):609-17. PubMed ID: 10386678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study.
    Salem JE; Bretagne M; Lebrun-Vignes B; Waintraub X; Gandjbakhch E; Hidden-Lucet F; Gougis P; Bachelot A; Funck-Brentano C;
    Arch Cardiovasc Dis; 2019 Nov; 112(11):699-712. PubMed ID: 31477476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sotalol and torsades de pointes ventricular tachycardia].
    Petersen HH; Sandøe E
    Ugeskr Laeger; 1996 May; 158(19):2711-6. PubMed ID: 8744073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population?
    Nuttall GA; Eckerman KM; Jacob KA; Pawlaski EM; Wigersma SK; Marienau ME; Oliver WC; Narr BJ; Ackerman MJ
    Anesthesiology; 2007 Oct; 107(4):531-6. PubMed ID: 17893447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study.
    Hafermann MJ; Namdar R; Seibold GE; Page RL
    Drug Healthc Patient Saf; 2011; 3():53-8. PubMed ID: 22046106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrocardiographic measures of repolarization heterogeneity are not predictive for Torsades de Pointes among undifferentiated patients with prolonged QTc: A case control study.
    Marill KA; Lopez S; Hark D; Spahr J; Shesh-Muthal K; Xue J; Rowlandson GI; Liu SW
    J Cardiovasc Electrophysiol; 2023 Jan; 34(1):166-176. PubMed ID: 36335640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The possible role of propofol in drug-induced torsades de pointes: A real-world single-center analysis.
    Abrich VA; Ramakrishna H; Mehta A; Mookadam F; Srivathsan K
    Int J Cardiol; 2017 Apr; 232():243-246. PubMed ID: 28100427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of droperidol and ondansetron on dispersion of ventricular repolarization: A randomized double-blind clinical study in anesthetized adult patients.
    Agámez Medina GL; González-Arévalo A; Gómez-Arnau JI; García del Valle S; Rubio JA; Esteban E; Pérez E
    Rev Esp Anestesiol Reanim; 2015 Nov; 62(9):495-501. PubMed ID: 25887095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?
    Romero J; Baldinger SH; Goodman-Meza D; Engstrom K; Valencia CR; Golive A; Medrano F; Rangasamy S; Makkiya M; Fisher JD; Gross J; Krumerman A; Kim S; Garcia MJ; Di Biase L; Ferrick KJ
    J Interv Card Electrophysiol; 2016 Jan; 45(1):37-45. PubMed ID: 26589717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes.
    Lazzerini PE; Laghi-Pasini F; Bertolozzi I; Morozzi G; Lorenzini S; Simpatico A; Selvi E; Bacarelli MR; Finizola F; Vanni F; Lazaro D; Aromolaran A; El Sherif N; Boutjdir M; Capecchi PL
    Heart; 2017 Nov; 103(22):1821-1829. PubMed ID: 28490617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome.
    Halkin A; Roth A; Lurie I; Fish R; Belhassen B; Viskin S
    J Am Coll Cardiol; 2001 Oct; 38(4):1168-74. PubMed ID: 11583899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Torsade de Pointes in a tertiary hospital population.
    Vandael E; Vandenberk B; Vandenberghe J; Pincé H; Willems R; Foulon V
    Int J Cardiol; 2017 Sep; 243():511-515. PubMed ID: 28576628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.